CAN (ON): Licensing and manufacturing agreement finalized

Indiva Limited has entered into a licensing and manufacturing agreement with Dycar Pharmaceuticals. "Pursuant to the Agreement, Dycar will immediately provide Indiva with non-dilutive financing of $3.6 million, $500,000 of which has been previously advanced, and an additional $4.5 million of non-dilutive financing over two instalments," the team with the company explains. "Such amounts will be used to finance the production and distribution, by Indiva, of certain Dycar-branded cannabis products (the “Dycar Products”). Sale proceeds from Dycar Products will be used to repay the financing. The Company and Dycar will also share additional sale proceeds of Dycar Products pursuant to the terms of the Agreement."

The Company's Board of Directors has also approved the grant of 2,977,333 stock options to directors, officers, employees and consultants of the Company. "The options granted are exercisable into common shares of the Company at a price of $0.40 per common share in accordance with TSX Policy 4.4, subject to the rules of the TSX Venture Exchange and the Company’s Stock Option Plan. The options have a term of five years and will expire on February 18, 2025. One-third of all options will vest on the first anniversary of the grant, one-third of all options will vest on the second anniversary of the grant and the final one-third of all options will vest on the third anniversary of the grant," the company concludes. 

For more information:
Indiva Limited
indiva.com  


Publication date:



Receive the daily newsletter in your email for free | Click here


Other news in this sector:


© MMJDaily.com 2020

Sign up for our daily Newsletter and stay up to date with all the latest news!

Subscribe I am already a subscriber